• In addition to routine vaccination for adolescents, MenACWY vaccine is also recommended for certain groups of people:
  • People at risk because of a serogroup A, C, W, or Y meningococcal disease outbreak
  • People with HIV
  • Anyone whose spleen is damaged or has been removed, including people with sickle cell disease
  • Anyone with a rare immune system condition called “persistent complement component deficiency”6
  • Anyone taking a type of drug called a complement inhibitor, such as eculizumab (also called Soliris®) or ravulizumab (also called Ultomiris®)
  • Microbiologists who routinely work with isolates of N. meningitidis
  • Anyone traveling to, or living in, a part of the world where meningococcal disease is common, such as parts of Africa
  • College freshmen living in residence halls
  • U.S. military recruits
    1. Page last reviewed: August 15, 2019Content source:National Center for Immunization and Respiratory Diseases, Issue date of VIS: August 15, 2019
Age,Years Recommendations
Australia92 15-19 MenB†
Canada93 12-24 MenC conjugate or MenACWY conjugate‡
MenB-4C for those who want to protect
against serogroup B infection
Europe94
Austria 11-13 MenACWY
Cyprus ≥2 MenACWY polysaccharide
(only on specific indications)
Czech Republic 13-17 MenACWY
≥18 MenACWY and MenB
France 2-24 MenC (catch-up)
Germany 2-17 MenC (catch-up)
Greece 11-12 MenACWY
≥13 MenACWY (catch-up)
Ireland 12-13 MenC
Italy 12-14 MenACWY
Liechtenstein 11-20 MenC (catch-up)
Poland 19 MenC
Spain 12 MenC
United Kingdom 13-15, 17-25 MenACWY conjugate§
New Zealand95 Adolescents/ young adults MenC or MenACWY vaccination
should be considered for those living or
planning to live in communal accommodation"
United States96,97 11-18 MenACWY (single dose at age 11 or 12 with
booster at age 16 years)
≥10 ≥ MenB (routine use for individuals ages ≥ 10
years at increased risk for MenB disease;
consideration for individuals ages 16-23 years
for short-term protection)
    1. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, VOL. 15, NO. 2, 459–469 https://doi.org/10.1080/21645515.2018.1528831

Feb. 2021: American college Health Association (ACHA) Guidelines Immunization Recommendations for College Students

  • Meningococcal Quadrivalent (A, C, W, Y) vaccine
  • Conjugate

    • Note: Polysaccharide vaccine is no longer available

  • VACCINATION SCHEDULE
  • Initial dose of conjugate vaccine: 11-12 yrs. of age • Booster dose: 16 yrs. of age
  • If initial dose given age 13-15 yrs.: booster dose at 16-18 yrs. of age
  • If initial dose given age ≥16 yrs., no booster dose required
    1. Immunization Recommendations for College Students, https://www.acha.org/documents/resources/guidelines/ACHA_Immunization_Recommendations_Feb2021.pdf

KSA - MOH vaccination schedule

UAE - MOH vaccination schedule

    1. DHA. (nd). Immunization Guidelines. [online] Available at: https://www.dha.gov.ae/Documents/HRD/Immunization%20Guidelines.pdf [Accessed 31 January 2021].

UK Uptake of a new meningitis vaccination programme amongst first-year undergraduate students aged 18–25 years

  • In 2015 meningococcal group W was declared endemic in the UK, with the MenACWY vaccination, subsequently introduced amongst adolescents and first year university students.

  • This study aimed to determine MenACWY uptake amongst students.
  • 401 participants were included in analysis.

    • Results

  • At 18 years-old: Vaccine uptake was 68.1%.

Compared to 18 years-old, the odds of vaccination were reduced for 19 year-olds (aOR = 0.087, 95% CI = 0.010– 0.729), 20 year-olds (aOR = 0.019, 95% CI = 0.002–0.161) and 21–25 year-olds (aOR = 0.003, 95% CI = <0.001–0.027)

Independent variable
Adjusted odds ratio (95% confidence interval)
P value
Age (years):
18
1
19
0.087 (0.010-0.729)
0.024
20
0.019(0.002-0.161)
<0.001
21-25
0.003 (<0.001-0.027)
<0.001

Conclusions

  • Older students are less likely to become vaccinated due to differing vaccination policy in this age-group.

      1. Sarah Blagden ,PLoS ONE 12(8): e0181817.https://doi.org/10.1371/journal.pone.0181817

    2019 USA coverage rate of MenACWY meningococcal vaccines in adolescents, more than 80%

      1. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, VOL. 15, NO. 2, 459–469 https://doi.org/10.1080/21645515.2018.1528831

    Effectiveness of Immunoprophylaxis in Suppressing Carriage of Neisseria Meningitidis in the Military Environment

    • Single-time throat culture samples were collected from professional 559 soldiers (302 unvaccinated vs. 257 vaccinated individuals with the quadrivalent conjugate vaccine ACYW-135).
    • Carriers:
    • Unvaccinated soldiers (9.6 %)
    • Vaccinated soldiers only (1.2 %).
    • The identified serogroups:
    • B (28%)
    • Y (25%)
    • C (22%)
    • Conclusion:
    • The initiation of mass vaccination with the quadrivalent conjugate vaccine ACYW-135 in the military environment seems an effective method of suppressing N. meningitidis carriage.
    Sociodemographic and behavioral variables
    Non-carriers of N. meningitidis
    (n = 52)
    Carriers of N. meningitidis
    ( n =32)
    p
    Age
    Mean ± SD
    30.2± 4.8
    29.3 ± 4.4
    0.407
    Range
    21.0-52.0
    22.0-43.0
    Median
    29.0
    29.0
    95 % CI
    29.8-30.6
    27.7-30.9
    Military rank
    Officer
    30 (5.7 %)
    3 (9.4 %)
    0.093
    Noncommissioned officer
    137 (26.1 %)
    3 (9.4 %)
    Private
    360 (68.3 %)
    26 (81.2 %)
    Sex
    Female
    7 (1.3 %)
    2 (6.3 %)
    0.093
    Male
    520 (98.7 %)
    30 (93.7 %)
    Palce of residence
    City
    341 (64.7 %)
    21 (65.6 %)
    0.916
    Country
    186 (35.3 %)
    11 (34.4 %)
    Smoking of cigarettes
    Yes
    174 (33.0 %)
    222 (68.7 %)
    0.001
    No
    353 (67.0 %)
    9 (31.3 %)
    Vaccination
    Vaccinated
    250 (47.4 %)
    3 (9.4 %)
    0.001
    Non-vaccinated
    277 (52.6 %)
    29 (90.6 %)
    p values for the differences between non-carriers and carriers of Neisseria meningitidis

      1. Korzeniewski, Advs Exp. Medicine, Biology - Neuroscience and Respiration (2015) 5: 19–28, DOI 10.1007/5584_2014_22, # Springer International Publishing Switzerland 2014, Published online: 14 October 2014

    MAT-BH-2200590-V1-AUG-2022